Related Experiment Video

Updated: Aug 23, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Infliximab is effective in acute but not chronic childhood ulcerative colitis

George H Russell1, Aubrey J Katz

  • 1Division of Pediatric Gastroenterology and Nutrition, Boston Floating Hospital, Tufts-New England Medical Center, Boston, Massachusetts, USA. grussell@tufts-nemc.org

Journal of Pediatric Gastroenterology and Nutrition
|July 23, 2004
PubMed

Insights

Infliximab effectively treated acute ulcerative colitis (UC) in pediatric patients, avoiding surgery. However, its effectiveness was reduced in patients with chronic steroid dependence.

Area of Science:

  • Pediatric Gastroenterology
  • Immunomodulatory Therapy
  • Inflammatory Bowel Disease

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting children.
  • Treatment resistance and steroid dependence are significant challenges in pediatric UC management.
  • Novel therapeutic agents are needed to improve outcomes and reduce colectomy rates.

Purpose of the Study:

  • To evaluate the efficacy and safety of infliximab in pediatric patients with ulcerative colitis.
  • To assess infliximab's effectiveness in different patient subgroups, including those with acute, steroid-refractory, and steroid-dependent UC.
  • To determine if infliximab can help avoid long-term steroid use and emergency colectomy.

Main Methods:

  • Open-label study of 14 pediatric patients with ulcerative colitis.
  • Patients were categorized into three groups based on disease severity and prior treatment.
  • Infliximab administered at 5 mg/kg/dose with follow-up using the Lichtiger Colitis Activity Index (LCAI).

Main Results:

  • All patients had severe UC (LCAI ≥11) at baseline.
  • High response rates observed in newly diagnosed (100%) and relapsed (75%) acute UC.
  • Lower response rate (20%) in patients with chronic steroid-dependent UC.

Conclusions:

  • Infliximab demonstrated effectiveness in treating acute pediatric ulcerative colitis.
  • Infliximab therapy helped avoid long-term steroid dependence and emergency colectomy.
  • Steroid-dependent patients showed reduced response to infliximab, indicating a need for tailored treatment strategies.
Abstract

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...